The Tisch Cancer Institute at Mount Sinai | Strategic Alliance Partners

CEO and physician James Bianco, a Bronx native and Mount Sinai alumnus, establishes endowment to address area of cancer with unmet need to bring more effective therapies to patients.

Immune checkpoint blockade has transformed the treatment paradigms of multiple advanced solid tumors-and bladder cancer is no exception.

Brett Miles, MD, DDS, discusses the potential of ADXS11-001 in HPV-associated head and neck cancer and other emerging therapies and treatment strategies.

Bart Barlogie, MD, world-renowned myeloma expert who introduced the first curative therapy, a multi-drug regimen known as Total therapy 3, for multiple myeloma joins the faculty of Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai.

A new test reveals which patients with leukemia and other blood disorders are likely to respond to treatment for graft-versus-host disease that develops after a stem cell transplant.

Sundar Jagannath, MD, discusses the latest research advances in myeloma, and how these steps will impact the future treatment paradigm for the disease.

In CT screening for lung cancer, the regimen of screening is a critical factor in diagnosing lung cancer early while limiting unnecessary tests and invasive procedures.

Randall F. Holcombe, MD, professor, Chief Medical Officer, Cancer, Mount Sinai Health System, discusses key takeaways for a practicing oncologist regarding the stool DNA test for colon cancer.

Melanoma care has fortunately undergone a whirlwind of changes over the past several years. Novel immunotherapies are perhaps the most exciting recent development in cancer care because patients can enjoy long-term benefit from these treatments, meaning that they are possibly "cured."

Cardiologists and cancer experts at The Mount Sinai Hospital have joined forces to establish its first Cardio-Oncology Clinic at The Tisch Cancer Institute.

Matthew D. Galsky, MD, assistant professor of medicine, Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, director, Genitourinary Medical Oncology, Tisch Cancer Institute at Mount Sinai Medical Center, discusses the role of ipilimumab in bladder cancer.

Immunotherapy can induce regressions of even advanced stage cancers, and many of these patients can have prolonged disease remissions.

Matthew D. Galsky, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, explains the mechanism of action of ipilimumab in bladder cancer.

Intervention doubled palliative care consultations; lowered in-hospital mortality and hospital readmission rates.

Over the past several years, several new approaches to treatment have prolonged and improved quality of life for patients with metastases.

Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the need for biomarkers for immunotherapies.

Over the past decade, it has become apparent that head and neck squamous cell carcinoma-including cancers of the mouth, throat, and larynx-is actually two separate diseases.

There have been waves of advancements in the treatment of multiple myeloma and further exploration of existing regimens and research into novel therapeutics hold the promise of advances.

Drs William Oh and Yixuan Gong discuss their research involving a whole-blood, 6-gene prognostic signature that has the potential to help personalize prostate cancer treatment.

Randall F. Holcombe, MD, Tisch Cancer Institute at Mount Sinai Medical Center, speaks about the use of aflibercept in patients with metastatic colorectal cancer.

William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses ongoing research into combination strategies for men with castration-resistant prostate cancer.

More potent versions of existing therapies are currently under development and showing considerable promise in early clinical trials for patients with multiple myeloma.

Over the past decade, the availability of new agents with varying mechanisms of action has greatly enhanced the treatment landscape in castration-resistant prostate cancer.

William K. Oh, MD, from the Tisch Cancer Institute, discusses strategies for sequencing the new therapies that have been approved for treating castration-resistant prostate cancer.

A whole-blood prognostic test based on gene-expression signatures may help predict risk for patients with castration-resistant prostate cancer.

Dr. Sundar Jagannath, from Mount Sinai Medical Center, Discusses the VANTAGE Trials

Dr. Marshall Posner, from Mount Sinai Medical Center, Discusses the Link Between HPV and Cancer